MDxHealth SA (MDXH) Stock Forecast, Price Target & Predictions
MDXH Stock Forecast
MDxHealth SA stock forecast is as follows: an average price target of $15.00 (represents a 472.52% upside from MDXH’s last price of $2.62) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
MDXH Price Target
The average price target for MDxHealth SA (MDXH) is $15.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 472.52% upside from MDXH's last price of $2.62.
MDXH Analyst Ratings
According to 11 Wall Street analysts, MDxHealth SA's rating consensus is 'Buy'. The analyst rating breakdown for MDXH stock is 0 'Strong Buy' (0.00%), 9 'Buy' (81.82%), 1 'Hold' (9.09%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).
MDxHealth SA Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 26, 2022 | Mark Massaro | BTIG | $15.00 | $8.19 | 83.15% | 472.52% |
The latest MDxHealth SA stock forecast, released on Aug 26, 2022 by Mark Massaro from BTIG, set a price target of $15.00, which represents a 83.15% increase from the stock price at the time of the forecast ($8.19), and a 472.52% increase from MDXH last price ($2.62).
MDxHealth SA Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $2.62 | $2.62 | $2.62 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of MDxHealth SA stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to MDxHealth SA's last price of $2.62. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Mar 07, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 07, 2024 | BTIG | Buy | Buy | Hold |
| May 31, 2023 | Noble Capital Markets | - | Outperform | Initialise |
| May 31, 2023 | Noble Capital | - | Outperform | Initialise |
| May 31, 2023 | UBS | - | Buy | Initialise |
| May 31, 2023 | Cowen & Co. | - | Outperform | Initialise |
| May 31, 2023 | Goldman Sachs | - | Neutral | Initialise |
| May 31, 2023 | Needham | - | Buy | Initialise |
| May 31, 2023 | William Blair | - | Outperform | Initialise |
| May 31, 2023 | RBC Capital | - | Outperform | Initialise |
MDxHealth SA's last stock rating was published by Piper Sandler on Mar 07, 2024. The company gave MDXH a "Overweight" rating, the same as its previous rate.
MDxHealth SA Financial Forecast
MDxHealth SA Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.70M |
| Avg Forecast | $27.09M | $26.45M | $26.05M | $25.41M | $26.09M | $24.71M | $25.10M | $22.85M | $22.36M | $21.11M | $20.86M | $18.13M | $18.56M | $18.21M | $15.22M | $13.56M |
| High Forecast | $27.29M | $26.65M | $26.25M | $25.60M | $26.29M | $24.90M | $25.29M | $23.02M | $22.52M | $21.13M | $21.01M | $18.26M | $18.70M | $18.35M | $15.34M | $13.66M |
| Low Forecast | $26.66M | $26.03M | $25.63M | $25.01M | $25.68M | $24.32M | $24.70M | $22.48M | $22.00M | $21.08M | $20.52M | $17.84M | $18.26M | $17.92M | $14.98M | $13.34M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% |
MDxHealth SA's average Quarter revenue forecast for Jun 23 based on 1 analysts is $15.22M, with a low forecast of $14.98M, and a high forecast of $15.34M. MDXH's average Quarter revenue forecast represents a 3.55% increase compared to the company's last Quarter revenue of $14.70M (Mar 23).
MDxHealth SA EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-7.08M |
| Avg Forecast | $-22.62M | $-22.09M | $-21.75M | $-21.22M | $-21.79M | $-20.64M | $-20.96M | $-19.08M | $-18.67M | $-17.63M | $-17.42M | $-15.14M | $-15.50M | $-15.21M | $-12.71M | $-11.32M |
| High Forecast | $-22.26M | $-21.74M | $-21.41M | $-20.88M | $-21.44M | $-20.31M | $-20.63M | $-18.78M | $-18.37M | $-17.60M | $-17.14M | $-14.90M | $-15.25M | $-14.97M | $-12.51M | $-11.14M |
| Low Forecast | $-22.79M | $-22.25M | $-21.92M | $-21.38M | $-21.95M | $-20.79M | $-21.12M | $-19.22M | $-18.81M | $-17.65M | $-17.55M | $-15.25M | $-15.61M | $-15.32M | $-12.81M | $-11.41M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.63% |
undefined analysts predict MDXH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than MDxHealth SA's previous annual EBITDA (undefined) of $NaN.
MDxHealth SA Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-14.70M |
| Avg Forecast | $-2.63M | $-3.00M | $-3.50M | $-4.17M | $-4.37M | $-5.19M | $-5.44M | $-6.87M | $-6.93M | $-7.58M | $-7.50M | $-8.17M | $-5.76M | $-8.19M | $-9.03M | $-11.27M |
| High Forecast | $-2.58M | $-2.94M | $-3.42M | $-4.08M | $-4.28M | $-5.08M | $-5.33M | $-6.73M | $-6.78M | $-7.03M | $-7.34M | $-8.00M | $-4.12M | $-8.02M | $-8.85M | $-11.04M |
| Low Forecast | $-2.66M | $-3.03M | $-3.53M | $-4.21M | $-4.41M | $-5.24M | $-5.50M | $-6.94M | $-7.00M | $-8.12M | $-7.57M | $-8.25M | $-7.00M | $-8.27M | $-9.12M | $-11.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.30% |
MDxHealth SA's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MDXH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
MDxHealth SA SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.60M |
| Avg Forecast | $20.37M | $19.89M | $19.59M | $19.11M | $19.62M | $18.58M | $18.87M | $17.18M | $16.81M | $15.87M | $15.68M | $13.63M | $13.95M | $13.69M | $11.44M | $10.19M |
| High Forecast | $20.52M | $20.04M | $19.73M | $19.25M | $19.77M | $18.72M | $19.01M | $17.31M | $16.93M | $15.89M | $15.80M | $13.73M | $14.06M | $13.80M | $11.53M | $10.27M |
| Low Forecast | $20.04M | $19.57M | $19.27M | $18.80M | $19.31M | $18.28M | $18.57M | $16.91M | $16.54M | $15.85M | $15.43M | $13.41M | $13.73M | $13.48M | $11.26M | $10.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.43% |
MDxHealth SA's average Quarter SG&A projection for Jun 23 is $11.44M, based on 1 Wall Street analysts, with a range of $11.26M to $11.53M. The forecast indicates a -21.62% fall compared to MDXH last annual SG&A of $14.60M (Mar 23).
MDxHealth SA EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.63 |
| Avg Forecast | $-0.10 | $-0.11 | $-0.13 | $-0.15 | $-0.16 | $-0.19 | $-0.20 | $-0.25 | $-0.25 | $-0.28 | $-0.27 | $-0.30 | $-0.21 | $-0.30 | $-0.33 | $-0.41 |
| High Forecast | $-0.09 | $-0.11 | $-0.13 | $-0.15 | $-0.16 | $-0.19 | $-0.20 | $-0.25 | $-0.25 | $-0.26 | $-0.27 | $-0.29 | $-0.15 | $-0.29 | $-0.32 | $-0.40 |
| Low Forecast | $-0.10 | $-0.11 | $-0.13 | $-0.15 | $-0.16 | $-0.19 | $-0.20 | $-0.25 | $-0.26 | $-0.30 | $-0.28 | $-0.30 | $-0.26 | $-0.30 | $-0.33 | $-0.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.52% |
According to undefined Wall Street analysts, MDxHealth SA's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MDXH previous annual EPS of $NaN (undefined).
MDxHealth SA Peer Comparison by Price Target
MDXH Forecast FAQ
Is MDxHealth SA a good buy?
Yes, according to 11 Wall Street analysts, MDxHealth SA (MDXH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 81.82% of MDXH's total ratings.
What is MDXH's price target?
MDxHealth SA (MDXH) average price target is $15 with a range of $15 to $15, implying a 472.52% from its last price of $2.62. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will MDxHealth SA stock go up soon?
According to Wall Street analysts' prediction for MDXH stock, the company can go up by 472.52% (from the last price of $2.62 to the average price target of $15), up by 472.52% based on the highest stock price target, and up by 472.52% based on the lowest stock price target.
Can MDxHealth SA stock reach $4?
MDXH's average twelve months analyst stock price target of $15 supports the claim that MDxHealth SA can reach $4 in the near future.
What are MDxHealth SA's analysts' financial forecasts?
MDxHealth SA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $98.75M (high $99.49M, low $97.18M), average EBITDA is $-82.465M (high $-81.151M, low $-83.083M), average net income is $-21.88M (high $-21.427M, low $-22.093M), average SG&A $74.25M (high $74.81M, low $73.07M), and average EPS is $-0.802 (high $-0.785, low $-0.81). MDXH's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $105M (high $105.79M, low $103.33M), average EBITDA is $-87.683M (high $-86.286M, low $-88.34M), average net income is $-13.303M (high $-13.028M, low $-13.433M), average SG&A $78.95M (high $79.54M, low $77.69M), and average EPS is $-0.487 (high $-0.477, low $-0.492).
Did the MDXH's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2023), MDxHealth SA's revenue was $14.7M, beating the average analysts' forecast of $13.56M by 8.42%. The company's EBITDA was $-7.081M, missing the average prediction of $-11.322M by -37.46%. MDxHealth SA's net income was $-14.701M, beating the average estimation of $-11.274M by 30.40%. The company's SG&A was $14.6M, beating the average forecast of $10.19M by 43.23%. Lastly, the company's EPS was $-0.63, beating the average prediction of $-0.413 by 52.49%